Core Viewpoint - The recent update of the American Academy of Dermatology (AAD) guidelines marks a significant shift in the treatment of atopic dermatitis, highlighting the Chinese innovative drug, Zeli Mei (Bimekizumab), which has received a "strong recommendation" for use in treatment [1][2][4] Group 1: Treatment Guidelines Update - The AAD's updated guidelines break the record for the shortest revision period of 23 months, indicating a rapid evolution in treatment standards for atopic dermatitis [1][2] - The guidelines are based on data from over 1,000 patients, including children aged 2 and above, demonstrating the clinical value of Bimekizumab [2][4] Group 2: Clinical Efficacy of Bimekizumab - Bimekizumab shows significant efficacy, with 54.4% of patients achieving over 75% skin lesion clearance after 8 weeks, and 46.2% meeting the IGA clinical cure standard [2] - Among children aged 2-17, the response rate for over 75% skin lesion clearance is as high as 69.2%, with 83.9% in the 7-11 age group [2] Group 3: Safety and Patient Compliance - The drug has a low risk of systemic exposure, with the main adverse effect being mild folliculitis, and no serious adverse events reported [2] - Bimekizumab offers a convenient application method, enhancing patient adherence and confidence in long-term disease management [4] Group 4: Industry Impact and Innovation - The approval and rapid market entry of Bimekizumab in both China and the U.S. signify a breakthrough for local innovation, positioning it as a first-line treatment option [4] - The drug's mechanism targets multiple pathways, overcoming limitations of traditional therapies, and is seen as a revolutionary option for millions of patients globally, especially children [3][4]